Repository logo
 
Publication

Determination of tranexamic acid in human plasma by UHPLC coupled with tandem mass spectrometry targeting sub-microgram per milliliter levels

dc.contributor.authorBarreiros, Luisa
dc.contributor.authorAmoreira, Júlia L.
dc.contributor.authorMachado, Sandia
dc.contributor.authorFernandes, Sara R.
dc.contributor.authorSilva, Eduarda M.P.
dc.contributor.authorSá, Paula
dc.contributor.authorKietaibl, Sibylle
dc.contributor.authorSegundo, Marcela A.
dc.date.accessioned2019-11-22T10:56:16Z
dc.date.available2021-03-03T01:30:35Z
dc.date.issued2019
dc.description.abstractTranexamic acid (TXA) is an antifibrinolytic drug, with the ability to inhibit lysine binding at plasminogen receptors, used in adult trauma patients with on-going or at risk of significant haemorrhage. To understand the pharmacokinetics and pharmacodynamics of this drug in variable age groups undergoing surgeries with high blood loss, effective methods for determination of TXA in biological samples at sub-μg mL−1 are still required. We describe herein the development and validation of a method based on ultra-high performance liquid chromatography coupled to triple quadrupole-tandem mass spectrometry to quantify TXA in human plasma. An inexpensive, simple and efficient sample clean-up was implemented, not requiring matrix-matching calibration. Sample preparation consisted in protein precipitation using acetonitrile containing 0.5% (v/v) formic acid, followed by hydrophilic interaction based chromatographic separation, with elution in isocratic mode using a combination of acetonitrile and water (75:25, v/v), with quantification of TXA based on selected reaction monitoring. Good linearity was achieved (r2 > 0.997) for TXA concentrations ranging from 30 to 600 ng mL−1, with LOD of 18 ng mL−1 in plasma. The developed method proved to be selective, sensitive, accurate (96.4–105.7% of nominal values) and precise (RSD ≤ 4.5%). TXA was found to be stable in plasma extracts standing 24 h at room temperature (20 °C) or in the autosampler, and after three freeze-thawing cycles. Mean recovery values of TXA spiked plasma samples were ≥91.9%. No significant matrix effects were observed. The proposed methodology was successfully applied to the clinical study of plasma samples recovered during scoliosis surgery of pediatric patients pretreatment with TXA.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1016/j.microc.2018.08.061pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.22/14914
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0026265X18308051?via%3Dihubpt_PT
dc.subjectAntifibrinolyticpt_PT
dc.subjectPharmacokineticspt_PT
dc.subjectDrug monitoringpt_PT
dc.subjectMass spectrometrypt_PT
dc.subjectPlasmapt_PT
dc.titleDetermination of tranexamic acid in human plasma by UHPLC coupled with tandem mass spectrometry targeting sub-microgram per milliliter levelspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage150pt_PT
oaire.citation.startPage144pt_PT
oaire.citation.titleMicrochemical Journalpt_PT
oaire.citation.volume144pt_PT
person.familyNameBarreiros
person.givenNameLuisa
person.identifier.ciencia-id611F-E0C5-0230
person.identifier.orcid0000-0003-3481-5809
person.identifier.ridD-7950-2013
person.identifier.scopus-author-id6508205485
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication1e66bacc-64de-4ecb-96b7-4c0e366cba57
relation.isAuthorOfPublication.latestForDiscovery1e66bacc-64de-4ecb-96b7-4c0e366cba57

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ART_LuísaBarreiros_2019.pdf
Size:
409.73 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: